NT157

NT157 (Tyrphostin NT157) is a selective IRS-1/2 inhibitor that induces Ser-phosphorylation and consequently the degradation of IRS-1/2. NT157 (Tyrphostin NT157) is a first-in-class anti-cancer agent that also targets Stat3 signaling pathway[1][2].

Product Specifications

CAS Number

[1384426-12-3]

Product Name Alternative

Tyrphostin NT157

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Insulin Receptor; STAT

Type

Reference compound

Related Pathways

JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Cancer; Endocrinology

Assay Protocol

https://www.medchemexpress.com/NT157.html

Purity

99.38

Solubility

DMSO : ≥ 30 mg/mL

Smiles

S=C(NCC1=CC(O)=C(O)C(O)=C1)/C=C/C2=CC(O)=C(O)C(Br)=C2

Molecular Formula

C16H14BrNO5S

Molecular Weight

412.26

Precautions

H302, H315, H319, H335

References & Citations

[1]Downregulated the Tyr-phosphorylation of IRS-1 in the MG-63 and U-2OS cells.|[2]Flashner-Abramson E, et al. Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling. Oncogene. 2016 May 19;35 (20) :2675-80.|[3]Ibuki N, et al. The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer. Mol Cancer Ther. 2014 Dec;13 (12) :2827-39.|[4]Ishii H, et al. miR-130a and miR-145 reprogram Gr-1+CD11b+ myeloid cells and inhibit tumor metastasis through improved host immunity. Nat Commun. 2018 Jul 4;9 (1) :2611.